Multiplex flow cytometry-based assay for quantifying tumor- and virus-associated antibodies induced by immunotherapies.

Autor:	Minott JA; Department of Pathobiology, University of Guelph, Guelph, ON, Canada., van Vloten JP; Department of Pathobiology, University of Guelph, Guelph, ON, Canada., Yates JGE; Department of Pathobiology, University of Guelph, Guelph, ON, Canada., Chan L; Department of Pathobiology, University of Guelph, Guelph, ON, Canada., Wood GA; Department of Pathobiology, University of Guelph, Guelph, ON, Canada., Viloria-Petit AM; Department of Biomedical Sciences, University of Guelph, Guelph, ON, Canada., Karimi K; Department of Pathobiology, University of Guelph, Guelph, ON, Canada., Petrik JJ; Department of Biomedical Sciences, University of Guelph, Guelph, ON, Canada., Wootton SK; Department of Pathobiology, University of Guelph, Guelph, ON, Canada., Bridle BW; Department of Pathobiology, University of Guelph, Guelph, ON, Canada.; ImmunoCeutica Inc., Cambridge, ON, Canada.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2022 Nov 16; Vol. 13, pp. 1038340. Date of Electronic Publication: 2022 Nov 16 (Print Publication: 2022).
DOI:	10.3389/fimmu.2022.1038340
Abstrakt:	Novel immunotherapies continue to be developed and tested for application against a plethora of diseases. The clinical translation of immunotherapies requires an understanding of their mechanisms. The contributions of antibodies in driving long-term responses following immunotherapies continue to be revealed given their diverse effector functions. Developing an in-depth understanding of the role of antibodies in treatment efficacy is required to optimize immunotherapies and improve the chance of successfully translating them into the clinic. However, analyses of antibody responses can be challenging in the context of antigen-agnostic immunotherapies, particularly in the context of cancers that lack pre-defined target antigens. As such, robust methods are needed to evaluate the capacity of a given immunotherapy to induce beneficial antibody responses, and to identify any therapy-limiting antibodies. We previously developed a comprehensive method for detecting antibody responses induced by antigen-agnostic immunotherapies for application in pre-clinical models of vaccinology and cancer therapy. Here, we extend this method to a high-throughput, flow cytometry-based assay able to identify and quantify isotype-specific virus- and tumor-associated antibody responses induced by immunotherapies using small sample volumes with rapid speed and high sensitivity. This method provides a valuable and flexible protocol for investigating antibody responses induced by immunotherapies, which researchers can use to expand their analyses and optimize their own treatment regimens. Competing Interests: B.W.B is the Chief Scientific Officer of ImmunoCeutica Inc., which is dedicated to the research and development of immunoceuticals. S.K.W. is a founder of Avamab Pharma Inc., which produces gene therapy vectors that express antibodies, and the senior scientific advisor for Cellastra Inc., which is dedicated to research and development of gene therapies targeting root causes of scarring. ImmunoCeutica Inc., Avamab Pharma Inc., and Cellastra Inc. did not provide any funding, nor did they have any role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest. (Copyright © 2022 Minott, van Vloten, Yates, Chan, Wood, Viloria-Petit, Karimi, Petrik, Wootton and Bridle.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu